JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 14, 2003; DOI: 10.1124/jpet.103.060673


0022-3565/04/3083-993-1001$20.00
JPET 308:993-1001, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.060673v1
308/3/993    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Márquez, N.
Right arrow Articles by Muñoz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Márquez, N.
Right arrow Articles by Muñoz, E.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Caffeic Acid Phenethyl Ester Inhibits T-Cell Activation by Targeting Both Nuclear Factor of Activated T-Cells and NF-{kappa}B Transcription Factors

Nieves Márquez, Rocío Sancho, Antonio Macho, Marco A. Calzado, Bernd L. Fiebich, and Eduardo Muñoz

Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Facultad de Medicina, Córdoba, Spain (N.M., R.S., A.M., M.A.C., E.M.); Neurochemistry Research Group, Department of Psychiatry, University of Freiburg Medical School, Freiburg, Germany (B.L.F.); and VivaCell Biotechnology GmbH, Denzlingen, Germany (B.L.F.)

Received September 30, 2003; accepted November 10, 2003.


    Abstract
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Caffeic acid phenethyl ester (CAPE), which is derived from the propolis of honeybee hives, has been shown to reveal anti-inflammatory properties. Since T-cells play a key role in the onset of several inflammatory diseases, we have evaluated the immunosuppressive activity of CAPE in human T-cells, discovering that this phenolic compound is a potent inhibitor of early and late events in T-cell receptor-mediated T-cell activation. Moreover, we found that CAPE specifically inhibited both interleukin (IL)-2 gene transcription and IL-2 synthesis in stimulated T-cells. To further characterize the inhibitory mechanisms of CAPE at the transcriptional level, we examined the DNA binding and transcriptional activities of nuclear factor (NF)-{kappa}B, nuclear factor of activated cells (NFAT), and activator protein-1 (AP-1) transcription factors in Jurkat cells. We found that CAPE inhibited NF-{kappa}B-dependent transcriptional activity without affecting the degradation of the cytoplasmic NF-{kappa}B inhibitory protein, I{kappa}B{alpha}. However, both NF-{kappa}B binding to DNA and transcriptional activity of a Gal4-p65 hybrid protein were clearly prevented in CAPE-treated Jurkat cells. Moreover, CAPE inhibited both the DNA-binding and transcriptional activity of NFAT, a result that correlated with its ability to inhibit phorbol 12-myristate 13-acetate plus ionomycin-induced NFAT1 dephosphorylation. These findings provide new insights into the molecular mechanisms involved in the immunomodulatory and anti-inflammatory activities of this natural compound.


Caffeic acid phenethyl ester (CAPE) is an active phenolic compound present in propolis, which is the generic name of a resinous product derived from the bark of conifer trees and carried by honeybees to their hives. The biological activities of propolis and CAPE have been extensively studied, and it has been shown that CAPE has antitumoral (Chiao et al., 1995Go; Huang et al., 1996Go) and anti-inflammatory properties (Mirzoeva and Calder, 1996Go; Michaluart et al., 1999Go; Fitzpatrick et al., 2001Go). However, CAPE inhibits the transcriptional activity of the COX-2 gene in epithelial cells (Michaluart et al., 1999Go), inducible nitric-oxide synthase gene expression, and nitric oxide production in macrophage cell lines (Song et al., 2002Go; Nagaoka et al., 2003Go). In addition, CAPE may suppress the eicosanoid synthesis (Mirzoeva and Calder, 1996Go) and the release of arachidonic acid from cell membranes (Michaluart et al., 1999Go). It has been recently shown that this phenolic compound is a potent inhibitor of mitogen-induced T-cell proliferation, lymphokine production (Ansorge et al., 2003Go), and NF-{kappa}B activation as well (Natarajan et al., 1996Go). However, the detailed inhibitory mechanisms at the molecular level of CAPE on T-cell activation are still unknown.

The signal transduction pathways triggered by the activation of the TCR/CD3 complex in T-cells lead to the immediate activation of transcription factors that regulate a variety of activation-associated genes. Many of them are cytokines and surface receptors that play an important role in coordinating the immune response (Crabtree and Clipstone, 1994Go). The signal transduction pathways involved in T-cell activation are initiated by the activation of phospholipase C-{gamma} by specific tyrosine kinases at the lipid rafts resulting in the hydrolysis of the phosphatidylinositol 4,5 bisphosphate and the generation of inositol (1,4,5) triphosphate and diacylglycerol. Although inositol (1,4,5) triphosphate mobilizes Ca2+ from intracellular stores, diacylglycerol mediates activation of protein kinase C family members (Baier, 2003Go). As a consequence of an increase of intracellular Ca2+ levels, several signaling pathways are activated (Lewis, 2001Go). For instance, calcineurin, a Ca2+-calmodulin dependent protein phosphatase, is activated and subsequently dephosphorylates the nuclear factor of activated T-cells (NFAT), allowing its nuclear shuttling (Rao et al., 1997Go). This transcription factor was first described as an inducible regulatory complex critical for transcriptional induction of IL-2 gene in activated T-cells (Shaw et al., 1988Go) but was subsequently shown to regulate the transcription of many other genes, including cytokines (IL-4, {gamma}-interferon, tumor necrosis factor-{alpha}, and granulocyte/macrophage-colony stimulating factor), cell surface receptors such as FasL and CD40L (Kiani et al., 2000Go), and regulatory enzymes such as COX-2 (de Gregorio et al., 2001Go). In the nucleus, NFAT binds to the DNA either alone or in conjunction with AP-1 proteins (Macian et al., 2001Go). Nevertheless, the coordinate induction and activation of the transcription factors NFAT, NF-{kappa}B, and AP-1 is required to regulate cytokine gene expression (Crabtree and Clipstone, 1994Go).

Stimulation via TCR-CD3 complex alone is sufficient for NFAT activation (Weiss and Littman, 1994Go), but in the case of NF-{kappa}B and AP-1 activation, a costimulatory signal, provided by CD28 receptors, is also required in antigen-stimulated T-cells (Edmead et al., 1996Go). The transcription factor NF-{kappa}B is one of the key regulators of genes involved in the immune/inflammatory response as well as in survival from apoptosis. NF-{kappa}B is an inducible transcription factor made up of homo- and heterodimers of p50, p65 (RelA), p52, RelB, and c-rel subunits that interacts with a family of inhibitory I{kappa}B proteins, of which I{kappa}B{alpha} is the best characterized (Karin and Ben-Neriah, 2000Go). In most cell types, these proteins sequester NF-{kappa}B in the cytoplasm by masking its nuclear localization sequence. Antigen stimulation in T-cells triggers a signaling pathway that results in the phosphorylation, ubiquitination, and subsequent degradation of I{kappa}B proteins, resulting in the translocation of NF-{kappa}B from the cytoplasm to the nucleus (Karin and Ben-Neriah, 2000Go). The prototypical, inducible NF-{kappa}B complex is a heterodimer containing p50 and p65, and in addition to the control of NF-{kappa}B activity exerted at the nuclear translocation level, there is increasing evidence for another complex level of regulation that is mediated by post-translational modifications of both subunits (Garcia-Piñeres et al., 2001Go; Nishi et al., 2002Go; Vermeulen et al., 2002Go).

In this paper, we studied the effect of CAPE on early and late T-cell activation events, and we demonstrate that CAPE inhibits antigen-induced proliferation and IL-2 production in human peripheral T-cells. Moreover, we show here, for the first time, that in addition to NF-{kappa}B, CAPE also targets the NFAT signaling pathway that is known to play a critical role in the immune response.


    Materials and Methods
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Cell Lines and Reagents. Jurkat cells (American Type Culture Collection, Manassas, VA) were maintained in exponential growth in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 1 mM Hepes, and the antibiotics penicillin (100 U/ml) and streptomycin (100 µg/ml) (Invitrogen, Barcelona, Spain). The Hela-Tet-On-Luc cell line was constructed by stable cotransfection of HeLa cells (American Type Culture Collection) following Tet-On system kit instructions (BD Biosciences Clontech, Basingstoke, UK). Briefly, this cell line contains two plasmids: the pTET-ON codifies constitutively for rtTA protein that, in response to doxycycline, gets active and binds to the pTRE2hyg-Luc starting the synthesis of luciferase gene. HeLa-Tet-On-Luc cell line was maintained in Dulbecco's modified Eagle's medium (Invitrogen) in the presence of 100 µg/ml of Hygromycin (Invitrogen) and 100 µg/ml of G418. Cells were maintained in a humid chamber at 37°C under 5% CO2. The mAb anti-CD25 antibody (clone ACT-1, PE-labeled) was from DAKO (Glostrap, Denmark) and the mAbs anti-CD69 (clone FN50, fluorescein isothiocyanate-labeled) and anti-ICAM-1 (clone HA58, PE-labeled) were from BD Biosciences PharMingen (San Diego, CA). Dual-color reagent mouse IgG1/fluorescein isothiocyanate + mouse IgG1/PE from DAKO (clone DAK-GO1 directed toward Aspergillus niger glucose oxidase) was used as negative control. The anti-I{kappa}B{alpha} mAb was a gift from R. T. Hay (St. Andrews, Scotland), and the rabbit polyclonal anti-NFAT1 was a gift from J. M. Redondo (CBM, Madrid, Spain). [{gamma}-32P]ATP (3.000 µCi/mmol) was purchased from ICN Pharmaceuticals (Costa Mesa, CA). All other reagents were from Sigma-Aldrich (Barcelona, Spain).

Plasmids. The NFAT-Luc plasmid contains three copies of the NFAT binding site of the IL-2 promoter fused to the luciferase gene (Durand et al., 1988Go). The KBF-Luc contains three copies of the major histocompatibility complex enhancer {kappa}B site upstream of the conalbumin promoter followed by the luciferase gene (Yano et al., 1987Go). The IL-2-Luc (–326 to +45 of the IL-2 promoter) plasmid was previously described (Durand et al., 1988Go). The plasmids pRSVGal4-DBD, pGal4-NFAT1 (1–415), and pGal4-NFAT1 (1–171) have already been described (Luo et al., 1996Go). The Gal4-p65 plasmid containing the C-terminal region of the human p65 (amino acids 286–551) fused to the Gal4 binding domain (Schmitz et al., 1995Go) was obtained from M. L. Schmitz (University of Bern, Switzerland). The Gal4-Luc reporter plasmid includes five Gal4 DNA-binding sites fused to the luciferase gene (Schmitz et al., 1995Go).

Isolation of Human Peripheral Mononuclear Cells and T-Cell Proliferation Assays. Human peripheral blood mononuclear cells (PBMC) from healthy adult volunteer donors were isolated by centrifugation of venous blood on Ficoll-Hypaque density gradients (Amersham Biosciences Inc., Piscataway, NJ). Cells (105) were cultured in triplicate in 96-well round-bottom microtiter plates (NUNC A/S, Roskilde, Denmark) in 200 µl of complete medium and stimulated with staphylococcal enterotoxin B (SEB) (1 µg/ml) or PHA (1 µg/ml) in the presence or absence of increasing concentrations of CAPE. A SEB-activation model was used, since it mimics T-cell activation induced by TCR and costimulators. The cultures were carried out for 3 days and pulsed with 0.5 µCi [3H]TdR/well (ICN Pharmaceuticals) for the last 12 h of culture. Radioactivity incorporated into DNA was measured by liquid scintillation counting.

Measurement of IL-2 Synthesis. PBMC (106/ml) were preincubated with CAPE for 30 min in complete medium. Thereafter, cells were treated with SEB (1 µg/ml) for 18 h. After culture, supernatants were harvested and centrifuged for 10 min at 10,000g, and the levels of IL-2 in the supernatant were measured by enzyme-linked immunosorbent assay (R&D Systems, Wiesbaden-Norderstedt, Germany) according to the instructions of the manufacturer. Experiments were carried out in triplicate.

Cytofluorimetric Analyses of Cell Surface Antigen and Cell Cycle. For cell cycle analyses and measurement of CD25, CD69, and ICAM-1 expression, PBMC (106/ml) were stimulated with SEB (1 µg/ml) in 24-well plates in a total volume of 2 ml of complete medium for 48 h in the presence or absence of CAPE (10 µM). Cell surface expression of CD25, CD69, and ICAM-1 antigens was measured by direct fluorescence using specific mAbs and analyzed by flow cytometry in an EPIC XL flow cytometer (Beckman Coulter, Fullerton, CA). For DNA profile analyses, cells were washed in PBS, fixed in ethanol (70% for 24 h at 4°C) followed by RNA digestion (Rnase-A; 50 U/ml) and propidium iodide (20 µg/ml) staining, and analyzed by cytofluorimetry. Ten thousand gated events were collected per sample, and the percentage of cells in every phase of the cell cycle was determined. The frequency of cells having undergone chromatinolysis was calculated by determining the sub G0/G1 fraction.

Isolation of Nuclear Extracts and Mobility Shift Assays. Jurkat cells (106/ml) were treated with the agonists in complete medium as indicated. Cells were then washed twice with cold PBS, and proteins from total cell extracts (for NF-{kappa}B, AP-1, and Sp-1 binding) or nuclear extracts (for NFAT binding) were isolated as previously described (Sancho et al., 2003Go). Protein concentration was determined by the Bradford method (Bio-Rad, Hercules, CA). For the electrophoretic mobility shift assay (EMSA), double-stranded oligonucleotides containing the consensus sites for NF-{kappa}B, AP-1, Sp-1 (Promega, Madison, WI) and NFAT 5'-GATCGGAGGAAAAACTGTTTCATACAGA AGGCGT-3' (distal NFAT site of human IL-2 promoter) were endlabeled with [{gamma}-32P]ATP. The binding reaction mixture contained 3 µg of nuclear extract (or 15 µg of total extracts), 0.5 µg poly(dI-dC) (Amersham Biosciences Inc., Piscataway, NJ), 20 mM Hepes (pH 7), 70 mM NaCl, 2 mM DTT, 0.01% NP40, 100 µg/ml bovine serum albumin, 4% Ficoll, and 100,000 cpm of endlabeled DNA fragments in a total volume of 20 µl. When indicated, 0.5 µl of rabbit anti-NFAT1 or preimmune serum was added to the standard reaction before the addition of the radiolabeled probe. For cold competition, a 100-fold excess of the double-stranded oligonucleotide competitor was added to the binding reaction. After 30 min incubation at 4°C (room temperature in the case of NFAT), the mixture was electrophoresed through a native 6% polyacrylamide (4% in the case of NFAT) gel containing 89 mM Tris-borate, 89 mM boric acid, and 1 mM EDTA. Gels were pre-electrophoresed for 30 min at 225 V and then for 2 h after loading the samples. These gels were dried and exposed to X-ray film at –80°C.

Transient Transfections and Luciferase Activity. Jurkat cells (106) were transfected with the indicated plasmids in Opti-MEM (Invitrogen) by using Lipofectin Reagent (Invitrogen) following the instructions of the manufacturer. Twenty-four hours after transfection, cells were preincubated with different concentrations of CAPE for half an hour and then stimulated as indicated for 6 h. Then, the cells were lysed in 25 mM Tris-phosphate (pH 7.8), 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol. Luciferase activity was measured using an Autolumat LB 9501 (Berthold Technologies, Bad Wildbad, Germany) following the instructions of the luciferase assay kit (Promega), and protein concentration was measured by the Bradford method. The background obtained with the lysis buffer was subtracted in each experimental value, and the specific transactivation was expressed as total RLU induction. All of the experiments were repeated at least three times.

Western Blots. Jurkat cells (106 cells/ml) were stimulated as indicated in the presence or absence of CAPE for the indicated periods of time. Cells were then washed with PBS and resuspended in lysis buffer [20 mM Hepes (pH 8.0), 0.35 M NaCl, 0.1 mM EGTA, 0.5 mM EDTA, 1 mM MgCl2, 20% Glycerol, 1 mM DTT, 1 µg/ml leupeptin, 0.5 µg/ml pepstatin, 0.5 µg/ml apronitin, and 1 mM phenylmethylsulfonyl fluoride] containing 0.5% NP40. Cells were incubated for 15 min in ice, and cellular proteins were obtained by centrifugation. Protein concentration was determined by Bradford assay (Bio-Rad), and 30 µg of proteins were boiled in Laemmli buffer and electrophoresed in 10% sodium dodecyl sulfate-polyacrylamide gel (I{kappa}B{alpha}) or in 6% sodium dodecyl sulfate-polyacrylamide gel (NFAT). Separated proteins were transferred to nitrocellulose membranes (0.5 A at 100 V; 4°C) for 1 h. Blots were blocked in Tris-buffered saline solution containing 0.1% Tween 20 and 5% nonfat dry milk overnight at 4°C, and immunodetection of specific proteins was carried out with primary antibodies using an enhanced chemiluminescence system (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK).


    Results
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
CAPE Inhibits Antigen-Specific T-Cell Proliferation and Cell Cycle Progression. It has been recently shown that CAPE inhibits mitogen-induced T-cell proliferation (Ansorge et al., 2003Go). Thus, we studied the effects of CAPE on several T-cell activation events induced by stimulation with the SEB. This enterotoxin is a T-cell superantigen that mimics T-cell activation induced by TCR and costimulators (Marrack and Kappler, 1990Go). In Fig. 1A, it is shown that DNA synthesis measured by [3H]TdR uptake in both PHA and SEB-stimulated T-cells was markedly inhibited in a concentration-dependent manner by CAPE. As a consequence of cell activation, primary T-cells progress to the S-phase and G2/M phases of the cell cycle, and in Fig. 1B, it is shown that unstimulated PBMC remained largely in the G0/G1 phase of the cell cycle. Three days following activation with SEB, T-cells were full cycling and progressed through the S, G2, and M phases of the cell cycle (37% of the cells), whereas pretreatment with CAPE (10 µM) almost completely prevented the entry of the cells in the S-phase of the cell cycle (Fig. 1B). Interestingly, no significant differences were found in the percentage of hypodiploid cells (sub G0/G1) between SEB and SEB plus CAPE-stimulated cells. These results indicate that, at the doses used, CAPE did not induce cytotoxicity or apoptosis in primary T-cells. T-cell activation involves the induction of several surface molecules, such as CD69, CD25, or ICAM-1, whose gene transcriptional regulation is highly dependent on NF-{kappa}B. Thus, the effect of CAPE on the cell surface expression of these activation markers was studied in SEB-stimulated primary T-cells. Figure 2 demonstrated that CAPE at 10 µM greatly inhibited not only the percentage of cells expressing the CD25, CD69, and ICAM-1 markers at the cell surface but also the relative intensity of fluorescence in the positive cells (relative intensity of fluorescence measured in gated positive cells).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1. Effect of CAPE on T-cell proliferation and on the progression of cell cycle. Human PBMC were stimulated with SEB (1 µg/ml) or PHA (1 µg/ml) in the presence or absence of increasing concentrations of CAPE for 72 h (A). [3H]Thymidine incorporation was measured by liquid scintillation counting and represented as the mean of dpm ± S.E. of three different experiments. PBMC were pretreated with CAPE (10 µM) and stimulated with SEB (1 µg/ml) for 72 h (B). The percentage of cells entering the S and G2/M phases of the cell cycle is indicated. The results are representative of four independent experiments.

 


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2. Effect of CAPE on SEB-induced cell surface expression of CD25, CD69, and ICAM-1. PMBC were treated as indicated for 48 h, and the expression of CD25, CD69, or ICAM-1 were detected by flow cytometry as described under Materials and Methods. The numbers represent the relative intensity of fluorescence for CD25, CD69, and ICAM-1 expression at the cell surface and are representative of three different experiments.

 

Effects of CAPE on IL-2 Synthesis and Promoter Activity. IL-2 represents one of the major growth factors for the clonal expansion of activated T-cells. Thus, we studied the effects of CAPE on SEB-induced IL-2 production in primary T-cells, and in Fig. 3, it is shown that this compound was able to inhibit the release of IL-2 in a concentration-dependent manner (with an IC50 of approximately 1 µM). Since IL-2 gene expression is regulated mainly at the transcriptional level, we investigated the regulation of IL-2 promoter in Jurkat cells transiently transfected with the luciferase reporter plasmid IL-2-Luc. After transfection, cells were preincubated with CAPE for 30 min, activated with PMA (20 ng/ml) plus ionomycin (1 µM) for 6 h, and tested for luciferase activity. CAPE efficiently inhibited PMA plus ionomycin-induced luciferase expression driven by the IL-2 promoter in a dose-dependent manner (Fig. 4A). The inhibitory effects of CAPE were not due to an interference with the transcriptional machinery or with the in vitro activity of the luciferase enzyme, since the inducible expression of luciferase mediated by doxycycline in Hela-Tet-On-Luc cells was not affected by CAPE at any of the concentrations tested (Fig. 4B).



View larger version (8K):
[in this window]
[in a new window]
 
Fig. 3. CAPE inhibits IL-2 production by primary T-cells. PBMC (106/ml) were preincubated with increasing concentrations of CAPE for 30 min and treated with SEB (1 µg/ml) for 18 h. Levels of IL-2 in the supernatant were measured by enzyme-linked immunosorbent assay according to the instructions of the manufacturer. Experiments were carried out in triplicate.

 


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4. Effect of CAPE on IL-2 promoter activity. Jurkat T-cells transfected with IL-2 promoter luciferase reporter plasmid were treated for 30 min with increasing concentrations of CAPE and then stimulated with PMA (20 ng/ml) plus ionomycin (1 µM) for 6 h, and luciferase activity was measured in the cell lysates (A). Results are the mean ± S.E. of three determinations expressed as fold induction (experimental RLU-background RLU/basal RLU-background RLU). B, HeLa-TET-on-Luc assay. Cells were pretreated with CAPE at the indicated doses, treated with doxycycline for 6 h, and the luciferase activity measured as indicated.

 

CAPE Inhibits NF-{kappa}B Transcriptional Activity. The transcriptional activity of many lymphokines, including IL-2, depends on the coordinated activation of several transcription factors, such as NFAT, NF-{kappa}B, and AP-1. First, we evaluated the effects of CAPE on the DNA binding of NF-{kappa}B, AP-1, and Sp-1 transcription factors, and we found that NF-{kappa}B was the only transcription factor inhibited by CAPE in a concentration-dependent manner (Fig. 5). The DNA-binding specificity was studied by supershift experiments with specific anti-p50 and anti-p65 (RelA) antibodies and by cold competition experiments with unlabeled competitors, and the heterodimer p50/p65 was identified as the main complex (data not shown; Sancho et al., 2003Go). Next, the effect of CAPE on the NF-{kappa}B transcriptional activity was evaluated by using the luciferase reporter construct KBF-Luc (Yano et al., 1987Go). Activation by PMA clearly increased (37-fold inductions) the luciferase gene expression driven by the NF-{kappa}B dependent promoter in Jurkat cells, and we found that, once more, CAPE effectively inhibited this activity in a dose-dependent manner (Fig. 6A). The inhibitory effect of CAPE on NF-{kappa}B inhibition was reversible, and CAPE removed from the cells after 2 h incubation did not affect the NF-{kappa}B-dependent luciferase activity in PMA-treated cells (data not shown). To investigate the level at which CAPE exerted its inhibitory effect on NF-{kappa}B activation, we stimulated Jurkat cells with PMA for different times in the presence or absence of CAPE (10 µM), and proteins from total cell extracts were analyzed for NF-{kappa}B-DNA binding activity by EMSA and for studying the steady-state levels of I{kappa}B{alpha} by Western blot. The kinetic experiments revealed a clear increase in NF-{kappa}B–DNA binding after 15 min of stimulation that slightly decreased through the time of stimulation; the increased DNA binding paralleled with degradation of I{kappa}B{alpha} that was more evident after 15 min of PMA stimulation and recovered after 60 min of stimulation. In Fig. 6B, it is shown that CAPE was able to prevent the NF-{kappa}B binding to DNA in PMA-stimulated Jurkat cells. However, under the same conditions, CAPE did not prevent I{kappa}B{alpha} degradation; even the recovery of I{kappa}B{alpha} protein to the basal levels, which also depend on NF-{kappa}B activation (Chiao et al., 1994Go), was delayed in the presence of CAPE, which did not affect the steady state levels of {alpha}-tubulin. These results are fully coincidental with those reported by Natarajan et al. (1996Go) in U937 cells and indicate that the NF-{kappa}B inhibitory effects of CAPE take place at a level downstream of I{kappa}B{alpha} degradation. Since the NF-{kappa}B heterodimer identified in PMA-stimulated Jurkat cells is composed of p50 and p65 subunits, and taking into account that p50 serves mainly as a DNA-binding subunit and p65 is the transcriptional active member of the complex (Karin and Ben-Neriah, 2000Go), we further analyzed whether CAPE directly inhibits p65-transcriptional activity. Thus, we performed cotransfection experiments using Gal4-p65, a fusion protein containing the transactivation domain of p65 (amino acids 286–551) and the DNA binding domain of the yeast Gal4 transactivator together with a reporter plasmid in which the luciferase gene is under the control of a Gal4-responsive element (Gal4-Luc). This system has the advantage that the Gal4 transactivator fusion protein is exclusively nuclear and regulated independently of I{kappa}Bs, thus, it can be used to study the basal levels of p65 transcriptional activity (Schmitz et al., 1995Go). The results presented in Fig. 6C revealed that transcriptional activity of Gal4-p65 was inhibited by the presence of CAPE in a concentration-dependent manner. However the inhibitory activity of CAPE was less evident using this heterologous Gal4-p65 system when compared with the endogenous NF-{kappa}B (Fig. 6A). Since the Gal4-p65 fusion protein only contains amino acids 286 to 551, it is likely that CAPE exerts its effect acting not only at the transactivation domain but also in other p65 domains.



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5. Effect of CAPE on NF-{kappa}B, AP-1, and Sp-1 DNA binding activity. Jurkat T-cells were incubated with the indicated doses of CAPE for 30 min and then stimulated with PMA (20 ng) plus ionomycin (1 µM) for either 30 (NF-{kappa}B detection) or 90 min (AP-1 and Sp-1 detection). The nuclear binding activity from total cell extracts were then assayed by EMSA using {gamma}-32P-labeled NF-{kappa}B, AP-1, and Sp-1 oligonucleotides.

 


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6. Effect of CAPE on the NF-{kappa}B activation pathway. Jurkat T-cells were transfected with the KBF-Luc reporter plasmid (A). Twenty-four hours later, the cells were incubated with increasing concentrations of CAPE for 30 min and then stimulated with PMA for 6 hours, and the luciferase activity was measured in the cell lysates. Results are the mean ± S.E. of three determinations expressed as fold induction. Jurkat T-cells were incubated with CAPE (10 µM) for 30 min and then treated with PMA for the indicated times (B). Protein extract was tested for NF-{kappa}B binding and for I{kappa}B{alpha} degradation and {alpha}-tubulin expression. Jurkat T-cells were transiently cotransfected with the plasmids Gal4-p65 and pGal4-Luc (C). Twenty-four hours after transfection, the cells were treated with increasing concentrations of CAPE for 6 h, and the luciferase activity was measured. Results are the mean ± S.E. of three different experiments, and the maximal activity of Gal4-Luc induced by p65-Gal4 (RLU/µg protein) was given a value of 1.

 

CAPE Inhibits NFAT Dephosphorylation and Transcriptional Activity. Transcriptional activation of NFAT requires its translocation to the nucleus, where it binds to specific consensus sites in the promoter region of IL-2 gene (Maggirwar et al., 1997Go). TCR signaling that activates NFAT can be mimicked by a combination of PMA plus the calcium ionophore, ionomycin. To study whether CAPE inhibits NFAT activation, we first performed electrophoretic mobility shift assays with nuclear extracts of Jurkat cells stimulated with PMA plus ionomycin in the presence or absence of increasing concentrations of CAPE. Using the distal NFAT site of the IL-2 promoter, we found a major complex that was retarded in PMA plus ionomycin-treated cells, and the binding to DNA of this complex was clearly inhibited in the presence of increasing concentrations of CAPE. This complex was characterized as NFAT1 by supershift experiments with an anti-NFAT1 antiserum and by cold competition experiments (Fig. 7A). To dissect the mechanism responsible for NFAT inhibition by CAPE, we studied the dephosphorylation of NFAT1 by Western blot using a specific antiserum against NFAT1. In Fig. 7B, it is shown that, upon PMA plus ionomycin treatment, NFAT1 was dephosphorylated in Jurkat cells and CAPE inhibited this dephosphorylation in a concentration-dependent manner. To further demonstrate the inhibitory effects of this plant-derived phenolic compound in NFAT transactivation activity, Jurkat cells were transfected with a luciferase reporter construct under the control of minimal promoter containing three NFAT binding sites. Activation by PMA plus ionomycin increased the luciferase gene expression driven by this promoter in Jurkat cells, and we found that CAPE effectively inhibited the inducible transcriptional activity of the NFAT promoter in a dose-dependent manner (Fig. 8A). Next, to explore the inhibitory mechanisms of CAPE on NFAT activation, a Gal4-derived reporter system was employed. Jurkat cells were cotransfected with the chimeric vector pGal4-NFAT1 (1–415), encoding the Gal4 DBD fused to amino acids 1 through 415 of human NFAT1, or the parental vector pRSV-Gal4-DBD along with the reporter plasmid Gal4-Luc. The fusion protein pGal4-NFAT1 (1–415) contains both the calcineurin-binding regulatory and transactivation domains. As shown in Fig. 8B, CAPE prevented the transactivation function of NFAT1 induced by PMA plus ionophore in a concentration-dependent manner. Strikingly, CAPE did not affect the transcriptional activity of the construct pGal4-NFAT1 (1–171) that contains only the transactivation domain of NFAT and is not regulated by the calcium-dependent calcineurin pathway that dephosphorylates NFAT1 (Luo et al., 1996Go). Altogether, our results strongly suggest that CAPE inhibits NFAT by targeting a component of the signaling pathways leading to NFAT dephosphorylation and not by interfering with the NFAT binding to DNA.



View larger version (69K):
[in this window]
[in a new window]
 
Fig. 7. Effect of CAPE on the NFAT activation pathway. (A) NFAT DNA-binding activity was analyzed for nuclear extracts from Jurkat T-cells stimulated for 2 h with PMA (20 ng) plus ionomycin (1 µM) in the absence or presence of increasing concentrations of CAPE. The specificity of the NFAT binding to DNA was demonstrated by supershift and cold competition assays (A, right panel). CAPE inhibits PMA plus ionomycin-induced NFAT dephosphorylation (B). Jurkat T-cells were treated as in A, and the phosphorylation status of NFAT1 was identified by Western blot analysis.

 


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8. Effect of CAPE on the NFAT transcriptional activity. Jurkat cells transiently transfected with NFAT-luc reporter plasmid were pretreated with the indicated doses of CAPE for 30 min followed by stimulation with PMA plus ionomycin for 6 h, the luciferase activity was measured in the cell lysates, and the transactivation index was expressed as fold induction (A). Jurkat cells were cotransfected by lipofection with 0.7 µg of a Gal4-Luc reporter plasmid per ml together with 0.3 µg of either the expression vector coding for the fusion protein Gal4-hNFAT1 (1–415) or hNFAT1 (1–171) (B). After 24 h, cells were pretreated or not with increasing doses of CAPE and further stimulated or not with PMA (20 ng/ml) plus ionomycin (1 µM) for 6 h. Results are the mean ± S.E. of three determinations expressed as RLU (106 cells).

 


    Discussion
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Since activated T-cells play a crucial role in the onset of several inflammatory diseases, the inhibition of transcription factors NF-{kappa}B and NFAT represents a rationale for the development of novel and safe anti-inflammatory agents. CAPE has been shown to be a pharmacologically safe compound with known anti-inflammatory, immunomodulatory, and anticarcinogenic properties (Huang et al., 1996Go; Michaluart et al., 1999Go; Ansorge et al., 2003Go), and we show here that CAPE is an effective in vitro inhibitor of both NFAT and NF-{kappa}B transcription factors. As a consequence, CAPE inhibits IL-2 gene transcription, IL-2R (CD25) expression, and proliferation in antigen-stimulated human T-cells.

Increasing evidence is accumulating to demonstrate that post-translational modifications of the NF-{kappa}B subunits are crucial for its transcriptional activity. Thus, modifications of critical sulfhydryl groups in p50 (Nishi et al., 2002Go) and in p65 (Garcia-Piñeres et al., 2001Go) may account for the NF-{kappa}B inhibitory activity of CAPE. It has been previously shown that curcumin and other compounds that are structurally similar to CAPE may covalently modify sulfhydryl groups by oxidation and alkylation reactions, thus affecting selectively cysteine residues of targeted proteins that control the transcription of inducible genes (Dinkova-Kostova et al., 2001Go). This biological activity of CAPE could explain the finding that this phenolic compound prevented the binding to DNA of the p50/p65 NF-{kappa}B in vitro and in vivo ((Natarajan et al., 1996Go and our results). However, CAPE also inhibits the transcriptional activity of the chimeric protein Gal4-p65 (amino acids 286–551) that contains the transactivation domain (Schmitz et al., 1995Go). Since this Gal4-p65 fusion protein is not able to interact with endogenous nuclear p50 and does not contain cysteine residues susceptible of modification, it is possible that other yet-to-be-identified mechanisms may account for the inhibitory effect of CAPE on NF-{kappa}B. It has been recently shown that IKK{alpha} translocates to the nucleus, where it phosphorylates histone H3, which is required for optimal NF-{kappa}B-dependent gene transcription (Yamamoto et al., 2003Go). Whether or not CAPE could interfere with this pathway at the nuclear level is an interesting possibility that warrants further research.

We show here, for the first time, that CAPE is also a potent inhibitor of the NFAT pathway, and our results suggest that the calcineurin phosphatase can represent one of the major targets for CAPE, since this compound inhibits NFAT dephosphorylation and nuclear binding to DNA. Moreover, CAPE did not affect the transcriptional activity of the fusion protein Gal4-NFAT (1–171), which does not require calcineurin activation to induce NFAT-dependent transcription. The catalytic subunit of calcineurin (calcineurin A) contains a phosphoesterase motif, which accommodates an active dinuclear metal center (Goldberg et al., 1995Go). Interestingly, in cell lysates from Jurkat cells, the calcineurin activity can be affected by both oxidation and reduction processes (Reiter et al., 1999Go; Sommer et al., 2000Go). Then, it is possible that phenolic compounds like CAPE and curcumin could interact with specific cysteine residues that seem to be critical for the calcium-dependent changes of the structural conformation of this phosphatase, impairing its activity (Tan et al., 1996Go).

The inhibitory effects of CAPE on other genes regulated by both NF-{kappa}B and NFAT transcription factors may be extended to nonlymphoid cells, such as human endothelial cells. Thus, angiogenesis, the formation of new blood vessels from the existing vasculature, occurs in many pathologies, including rheumatoid arthritis, atherosclerosis, and tumor growth (Sullivan and Bicknell, 2003Go). It has been reported that COX-2 plays an important role in such conditions, as overexpression of COX-2 in transformed cells (Michaluart et al., 1999Go) and in the joints of rheumatoid arthritis patients has been described (Woods et al., 2003Go). Angiogenesis regulation involves a complex signaling network in which inducible expression of COX-2 and subsequent prostaglandins synthesis plays a central role (Woods et al., 2003Go). It has been described that both NF-{kappa}B and NFAT participate in COX-2 gene transcriptional regulation, the calcium/calcineurin pathway being essential for COX-2 transcription not only in endothelial (Hernandez et al., 2001Go) but also in T-cells (Iñiguez et al., 2000Go). Accordingly, COX-2 gene transcription has been reported to be inhibited by CAPE through an NF-{kappa}B-independent pathway in oral epithelial cells (Michaluart et al., 1999Go), suggesting that additional elements at the COX-2 promoter are targeted by CAPE. A detailed analysis of COX-2 promoter in T-cells has identified two NFAT binding sites within this region, which are essential for COX-2 expression (Iñiguez et al., 2000Go). Since CAPE has been described as a potent NF-{kappa}B inhibitor, and we have reported here that NFAT is also inhibited by CAPE, it is likely that COX-2 gene inhibition mediated by CAPE is the consequence of the combined inhibitory effects of both NF-{kappa}B and NFAT transcription factors. In this sense, this COX-2 inhibitory activity of CAPE could explain the potential use of this natural compound in the treatment of disease conditions such as tumor growth, rheumatoid arthritis, and atherosclerosis, in which angiogenesis plays a key role.


    Acknowledgements
 
We thank Dr. Juan M. Redondo (CBM-UAM, Madrid, Spain) for the anti-NFAT1 antisera, Dr. R.T. Hay (CBMS, St. Andrews, Scotland) for the mAb 10B, and colleagues Dr. L. Schmitz (Bern, Switzerland) and Dr. Manuel López-Cabrera (Hospital de la Princesa, Madrid, Spain) for providing plasmids. We also thank Carmen Cabrero-Doncel for assistance with the manuscript.


    Footnotes
 
This work was supported by Ministerio de Ciencia y Tecnología Grant SAF2001-0037-C04-02 (to E.M.) and European Union Grant QLK3-CT-2000-00463 (to E.M. and B.F.). A.M. was supported by Ministerio de Ciencia y Tecnología Grant SAF2002-01157.

DOI: 10.1124/jpet.103.060673.

ABBREVIATIONS: CAPE, caffeic acid phenethyl ester; AP-1, activator protein-1; EMSA, electrophoretic mobility shift assay; I{kappa}B, {kappa}B inhibitor; NFAT, nuclear factor of activated cells; NF-{kappa}B, nuclear factor-{kappa}B; PBMC, peripheral blood mononuclear cells; TCR, T-cell receptor; IL, interleukin; mAb, monoclonal antibody; ICAM-1, intercellular adhesion molecule-1; SEB, staphylococcal enterotoxin B; PHA, phytohemagglutinin; PBS, phosphate-buffered saline; Sp-1, specificity protein 1; DTT, dithiothreitol; RLU, relative light units; PMA, phorbol 12-myristate 13-acetate; COX-2, cyclooxygenase-2; PE, phycoerythrin.

Address correspondence to: Dr. Eduardo Muñoz, Dpto. de Biología Celular, Fisiología e Inmunología. Facultad de Medicina. Avda. de Menéndez Pidal s/n, 14004 Córdoba, Spain. E-mail: fi1muble{at}uco.es


    References
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

Ansorge S, Reinhold D, and Lendeckel U (2003) Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch [C] 58: 580–589.

Baier G (2003) The PKC gene module: molecular biosystematics to resolve its T-cell functions. Immunol Rev 192: 64–79.[CrossRef][Medline]

Chiao C, Carothers AM, Grunberger D, Solomon G, Preston GA, and Barrett JC (1995) Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res 55: 3576–3583.[Abstract/Free Full Text]

Chiao PJ, Miyamoto S, and Verma IM (1994) Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci USA 91: 28–32.[Abstract/Free Full Text]

Crabtree GR and Clipstone NA (1994) Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 63: 1045–1083.[CrossRef][Medline]

de Gregorio R, Iñiguez MA, Fresno M, and Alemany S (2001) Cot kinase induces cyclooxygenase-2 expression in T-cells through activation of the nuclear factor of activated T-cells. J Biol Chem 276: 27003–27009.[Abstract/Free Full Text]

Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P (2001) Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci USA 98: 3404–3409.[Abstract/Free Full Text]

Durand DB, Shaw JP, Bush MR, Replogle RE, Belagaje R, and Crabtree GR (1988) Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol Cell Biol 8: 1715–1724.[Abstract/Free Full Text]

Edmead CE, Patel YI, Wilson A, Boulougouris G, Hall ND, Ward SG, and Sansom DM (1996) Induction of activator protein (AP)-1 and nuclear factor-kappaB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. J Immunol 157: 3290–3297.[Abstract]

Fitzpatrick LR, Wang J, and Le T (2001) Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats. J Pharmacol Exp Ther 299: 915–920.[Abstract/Free Full Text]

Garcia-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, and Merfort I (2001) Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276: 39713–39720.[Abstract/Free Full Text]

Goldberg J, Huang HB, Kwon YG, Greengard P, Nairn AC, and Kuriyan J (1995) Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature (Lond) 376: 745–753.[CrossRef][Medline]

Hernandez GL, Volpert OV, Iñiguez MA, Lorenzo E, Martinez-Martinez S, Grau R, Fresno M, and Redondo JM (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T-cells and cyclooxygenase 2. J Exp Med 193: 607–620.[Abstract/Free Full Text]

Huang MT, Ma W, Yen P, Xie JG, Han J, Frenkel K, Grunberger D, and Conney AH (1996) Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 17: 761–765.[Abstract/Free Full Text]

Iñiguez MA, Martinez-Martinez S, Punzon C, Redondo JM, and Fresno M (2000) An essential role of the nuclear factor of activated T-cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275: 23627–23635.[Abstract/Free Full Text]

Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621–663.[CrossRef][Medline]

Kiani A, Rao A, and Aramburu J (2000) Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12: 359–372.[CrossRef][Medline]

Lewis RS (2001) Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 19: 497–521.[CrossRef][Medline]

Luo C, Burgeon E, and Rao A (1996) Mechanisms of transactivation by nuclear factor of activated T-cells-1. J Exp Med 184: 141–147.[Abstract/Free Full Text]

Macian F, Lopez-Rodriguez C, and Rao A (2001) Partners in transcription: NFAT and AP-1. Oncogene 20: 2476–2489.[CrossRef][Medline]

Maggirwar SB, Harhaj EW, and Sun SC (1997) Regulation of the interleukin-2 CD28-responsive element by NFATp and various NF-kappaB/Rel transcription factors. Mol Cell Biol 17: 2605–2614.[Abstract]

Marrack P and Kappler J (1990) The staphylococcal enterotoxins and their relatives. Science (Wash DC) 248: 705–711.[Abstract/Free Full Text]

Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, Koboldt C, Mestre JR, Grunberger D, Sacks PG, Tanabe T, et al. (1999) Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res 59: 2347–2352.[Abstract/Free Full Text]

Mirzoeva OK and Calder PC (1996) The effect of propolis and its components on eicosanoid production during the inflammatory response. Prostaglandins Leukotrienes Essent Fatty Acids 55: 441–449.[CrossRef][Medline]

Nagaoka T, Banskota AH, Tezuka Y, Midorikawa K, Matsushige K, and Kadota S (2003) Caffeic acid phenethyl ester (CAPE) analogues: potent nitric oxide inhibitors from the Netherlands propolis. Biol Pharm Bull 26: 487–491.[CrossRef][Medline]

Natarajan K, Singh S, Burke TR, Jr., Grunberger D, and Aggarwal BB (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA 93: 9090–9095.[Abstract/Free Full Text]

Nishi T, Shimizu N, Hiramoto M, Sato I, Yamaguchi Y, Hasegawa M, Aizawa S, Tanaka H, Kataoka K, Watanabe H, and Handa H (2002) Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J Biol Chem 277: 44548–44556.[Abstract/Free Full Text]

Rao A, Luo C, and Hogan PG (1997) Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15: 707–747.[CrossRef][Medline]

Reiter TA, Abraham RT, Choi M, and Rusnak F (1999) Redox regulation of calcineurin in T-lymphocytes. J Biol Inorg Chem 4: 632–644.[CrossRef][Medline]

Sancho R, Calzado MA, Di Marzo V, Appendino G, and Muñoz E (2003) Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol 63: 429–438.[Abstract/Free Full Text]

Schmitz ML, dos Santos Silva MA, and Baeuerle PA (1995) Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J Biol Chem 270: 15576–15584.[Abstract/Free Full Text]

Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, and Crabtree GR (1988) Identification of a putative regulator of early T-cell activation genes. Science (Wash DC) 241: 202–205.[Abstract/Free Full Text]

Sommer D, Fakata KL, Swanson SA, and Stemmer PM (2000) Modulation of the phosphatase activity of calcineurin by oxidants and antioxidants in vitro. Eur J Biochem 267: 2312–2322.[Medline]

Song YS, Park EH, Hur GM, Ryu YS, Lee YS, Lee JY, Kim YM, and Jin C (2002) Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity. Cancer Lett 175: 53–61.[CrossRef][Medline]

Sullivan DC and Bicknell R (2003) New molecular pathways in angiogenesis. Br J Cancer 89: 228–231.[CrossRef][Medline]

Tan RY, Mabuchi Y, and Grabarek Z (1996) Blocking the Ca2+-induced conformational transitions in calmodulin with disulfide bonds. J Biol Chem 271: 7479–7483.[Abstract/Free Full Text]

Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, and Haegeman G (2002) Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 64: 963–970.[CrossRef][Medline]

Weiss A and Littman DR (1994) Signal transduction by lymphocyte antigen receptors. Cell 76: 263–274.[CrossRef][Medline]

Woods JM, Mogollon A, Amin MA, Martinez RJ, and Koch AE (2003) The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74: 282–290.[CrossRef][Medline]

Yamamoto Y, Verma UN, Prajapati S, Kwak YT, and Gaynor RB (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature (Lond) 423: 655–659.[CrossRef][Medline]

Yano O, Kanellopoulos J, Kieran M, Le Bail O, Israel A, and Kourilsky P (1987) Purification of KBF1, a common factor binding to both H-2 and beta 2-microglobulin enhancers. EMBO (Eur Mol Biol Organ) J 6: 3317–3324.[Medline]


This article has been cited by other articles:


Home page
J. Nutr.Home page
Y.-J. Surh, J. K. Kundu, H.-K. Na, and J.-S. Lee
Redox-Sensitive Transcription Factors as Prime Targets for Chemoprevention with Anti-Inflammatory and Antioxidative Phytochemicals
J. Nutr., December 1, 2005; 135(12): 2993S - 3001S.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Hishikawa, T. Nakaki, and T. Fujita
Oral Flavonoid Supplementation Attenuates Atherosclerosis Development in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 442 - 446.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.060673v1
308/3/993    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Márquez, N.
Right arrow Articles by Muñoz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Márquez, N.
Right arrow Articles by Muñoz, E.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition